

Prescribing and Medicines Optimisation Guidance

Issue: 71

Date: 22nd June 2022

1. Cardiovascular disease webinars – message from the Primary Care Cardiovascular Disease Optimisation Group

We welcome you to the second of three MS Teams meetings over the summer to cover key areas of the Cardiovascular Disease prevention agenda which is an important part of the NHS England Long Term Plan and integral to the delivery of the PCN DES IIF.

To register for Webinar 2 - 6th July 1-2 pm please follow this [link](#).

Webinar 2: Edoxaban and Preventing Stroke in Atrial Fibrillation – Wed 6th July 1-2pm will cover:

1. Atrial Fibrillation – why it is important to find and treat with OAC (edoxaban first line for AF, as per PCN DES). Secondary care and the HIOW perspective.
Dr Dominic Kelly, Consultant Cardiologist, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust
2. Oral Anticoagulation and use of edoxaban as DOAC of choice in Stroke Prevention in Atrial Fibrillation.
Dr Udaya Reddy, Consultant Haematologist, Thrombosis Lead, Basingstoke and North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust
3. Practical aspects of searching and prioritising patients in primary care.
Liz Corteville, South West System Lead Pharmacist and Deputy to the Associate Director – Medicines Optimisation, NHS Hampshire, Southampton and Isle of Wight CCG
4. Case studies, discussion, questions and problem-solving.

Anyone working in any practice in HIOW is welcome to attend.

Coming soon: Webinar 3: Familial Hypercholesterolaemia – Thu 22nd Sep 1-2pm

2. Physical health monitoring for psychotropic medication guidelines ([Link](#))

Southern Health NHS Foundation Trust have updated their guidelines for physical health monitoring for psychotropic medication guidelines. These can be found on the GP portal at the link above.

3. NICE guidelines: Gout: diagnosis and management (NG219) ([Link](#))

This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

4. Macrogol 8.5g sachets

Please take care when prescribing macrogol products.

Macrogol compound oral powder sachets NPF sugar free	£4.29 (30 sachets)
Macrogol 3350 oral powder 8.5g sachets sugar free	£99.85 (28 sachets)

This size of sachet is specific to Transisoft® brand only and so only the Transisoft® brand can be dispensed. Please select Macrogol compound oral powder sachets NPF sugar free when prescribing macrogol.

5. Tropicamide safety information

Sussex Police have asked for caution when supplies are made of tropicamide eye drops:

Tropicamide eye drops have been found in recreational areas where children/youths frequent in the Lewes area. The product is a POM and used as an antimuscarinic ophthalmic solution. Empty bottles have been found but no evidence of injecting at this time, please be aware should it catch on causing an influx of young people requesting these eye drops.

Tropicamide is an antimuscarinic ophthalmic solution. Recently, it is reported to be used intravenously for recreational purposes. Misuse of the drug may lead to several effects such as slurred speech, unconsciousness, hallucinations, dysphoria, suicidal feelings, convulsions, and tachycardia.

6. Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause ([Link](#))

This joint position statement provides guidance to healthcare practitioners who offer care to women experiencing the menopause. The menopause transition can have a significant impact on many women, with more than 75% experiencing menopausal symptoms and a quarter describing their symptoms as severe. A third experience long-term symptoms, which may last as much as 7 years or longer. The aim of this position statement is to provide evidence-based recommendations on best practice in line with current national and international guidelines and recommendations. It recommends an individualised approach in assessing women

going through the menopause, with reference to lifestyle advice, diet modification as well as discussing the role of interventions including HRT.

7. SPS guidance: Parkinson's disease medicines formulations for adults with swallowing difficulties ([Link](#))

This guidance covers the interaction between Parkinson's disease medicines and food, licensed medicines in suitable formulations, licensed medicines used in an unlicensed manner and special-order medicines.

8. SPS advice: Using chloramphenicol in breastfeeding ([Link](#))

Topical chloramphenicol can be used in women who are breastfeeding with caution and monitoring, but systemic chloramphenicol is not recommended, as discussed in this resource. The advice applies to full term and healthy infants.

**Prepared by Anita Bhardwaj, Sue Wakelin and Dr Emma Harris
On behalf of the Hampshire, Southampton and IoW CCG Medicines Optimisation
Team**

Previous bulletins can be found at: <https://gp-portal.westhampshireccg.nhs.uk/medicines/covid-19-medicines-information/covid-19-medicines-optimisation-bulletins/>